Under the terms of the Agreement, SUTIMCo will help Capwave in developing and commercializing its technology for a period of three years at $77,500 per month.
SUTIMCo launches and manages businesses in health & wellness, energy/environmental, advanced materials, sensors and electronic technology ventures to build upon the research of a host of prestigious Universities across the United States.
Capwave said its portable Enzyme-Linked ImmunoSorbent Assay (ELISA) test platform is capable of detecting bioweapons (anthrax, bacillus globigii), biomarkers (cancer, stem cells), toxins (E. coli and salmonella in foodborne illness), contaminants and diseases (both viral and bacterial).
SUTIMCo operates as a venture accelerator, offering development services to start-up companies for up to three years.
